Results, Setbacks

AstraZeneca’s respiratory team acknowledges its latest setback, trial flops

AstraZeneca’s respiratory R&D group has another setback to report.

The pharma giant’s partners at Dynavax Technologies $DVAX filed a statement with the SEC today noting that the research team at AstraZeneca informed them that their Phase IIa trial of the TLR9 agonist AZD1419 had flopped.

There aren’t a lot of details. Dynavax wrote:

AstraZeneca will now review the full data before deciding on the next steps for the AZD1419 program. The data will be presented at a future medical meeting.

Just a few weeks ago AstraZeneca posted mixed detailed results for its PT010 for COPD. And that arrived just days after AstraZeneca was forced to explain that its drug Bevespi Aerosphere (glycopyrronium/formoterol fumarate) couldn’t beat out GSK’s Anoro (umeclidinium/vilanterol) on peak forced expiratory volume in one second (FEV1). Measuring trough FEV1, the other co-primary endpoint in the study, AstraZeneca’s inhaler performed worse. 

AstraZeneca has had much greater success in oncology, but needs to perform in all of its core R&D areas if it wants to achieve a complete turnaround, as promised by CEO Pascal Soriot.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->